Cancer Therapy With Radiolabeled Antibodies An Overview

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cells

“…Using a chimeric MoAb like rituximab in radioimmunotherapy could strongly reduce HAMA (human anti-mouse antibody) responses in patients. However, the prolonged biological half-life of the humanized MoAbs could cause problems with increased radiation dose to normal tissues, and hence a decreased therapeutic index, when isotopes with longer half-life (days) are utilized (Bruland, 1995;Multani and Grossbard, 1999). The use of a relatively shortlived isotope like 211 At will make those differences in biological half-life less relevant.…”

Absorbed dose estimates at the cellular level for 186Re and 188Re

“…In the case of 188 Re, we found 0.4545 g-Gy/MBq-h. However, we found significantly (Bardies and Chatal, 1994) 768 (Nahum, 1996) 201 Tl 20.68 (Unak, 1997) 44.748 (Unak, 1997) 20 (Rao et al,1985) 43.3 (Kassis et al, 1983) 43.5 (Ftacnikova and Bohm, 2000) 204 Tl 1.10 (this study) 245.219 (Unak, 1997) 243 (Kassis et al, 1983) 55 Fe 5.341 (Unak, 1997) 5.803 (Unak, 1997) 4.75 (Humm et al, 1994) 4.0471.66 (Humm et al, 1994) 51 Cr 5.420 (Unak, 1997) 3.652 (Unak, 1997) 5.42 (Kassis et al, 1983) 3.65 (Vezza et al, 1987) 99m Tc 5.15 (Unak, 1997) 17.286 (Unak, 1997) 5.13 (Makrigiorgos et al, 1989) 17.28 (Makrigiorgos et al, 1989) 16.2 (Ftacnikova and Bohm, 2000) Bruland has reported that in a radical course of radiotherapy a total of 50-80 Gy must be delivered to the tumor (Bruland, 1995). Fig.…”

Radiotherapy in Scandinavia

“…In general, the clinical therapeutic use of radiolabelled antibodies has been disappointing among patients with solid cancers (9). P. Abrams, Seattle, presented preclinical and clinical data on a pre-targeting/multistep approach using streptavidin-conjugated antibody followed by a clearing step using biotinylated human serum albumin.…”